{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-203993","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.923733+00:00","generated_at":"2026-05-14T23:58:50.425695+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026","bullets":["Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.","Cash and investments $419.7M as of March 31, 2026, including $59.9M from ATM. Expected runway into 2H 2028.","Enrolled Phase 1b enozertinib monotherapy in 1L EGFR exon20 insertion NSCLC; data expected 2H 2026.","R&D expenses $31.4M in Q1 2026 vs $24.6M in Q1 2025, driven by rinzimetostat and enozertinib advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-203993","json":"https://secwatch.observer/filing/0001193125-26-203993.json","markdown":"https://secwatch.observer/filing/0001193125-26-203993.md","text":"https://secwatch.observer/filing/0001193125-26-203993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/0001193125-26-203993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/oric-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:58:50.425695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"024d7e914880017cabe9d5dbb0dadb5289c50c06","claim":"Oric Pharmaceuticals, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"ORIC Pharmaceuticals, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526203993/0001193125-26-203993-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}